The Risk of Antihypertensive Drug among Breast Cancer Patient: A Systematic Review and Meta-analysis

Open Access Macedonian Journal of Medical Sciences

View Publication Info
Field Value
Title The Risk of Antihypertensive Drug among Breast Cancer Patient: A Systematic Review and Meta-analysis
Creator Wiranata, Sinta
Anjani, Ida Ayu Widya
Wulandari, Putri Ayu
Indrakusuma, Anak Agung Bagus Putra
Sadeva, I Gede Krisna Arim
Wisnawa, Ayu Dilia Febriani
Fajar, Jonny Karunia
Prabawa, I Putu Yuda
Adiputra, Putu Anda Tusta
Sudarsa, I Wayan
Lestari, Anak Agung Wiradewi
Wihandani, Desak Made
Supadmanaba, I Gede Putu
Subject Breast cancer
Antihypertensive drugs
Risk factors
Description BACKGROUNDS: Breast cancer or breast carcinoma is the most common type of malignancy in women globally. According to the previous studies that indicate the usage of antihypertensive drugs may become a risk factor of cancer (beta-blockers [BBs], calcium channel blockers [CCBs], and diuretics). Both angiotensin-converting enzymes inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), on the other hand, have been associated to an increased or decreased risk of breast cancer.

AIM: To compare each type of antihypertensive medicines as a risk factor for breast cancer, we did a systematic review and meta-analysis of current evidence.

METHODS: We utilized the terms “antihypertensive”, “anti-hypertensive”, “anti-hypertensive medications”, “breast cancer”, “risk”, “case control”, and “cohort” in PubMed, ScienceDirect, and Google Scholar databases.

RESULTS: Our data calculation found that the risk of antihypertensive drugs was significantly different in overall analysis (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.42–0.83, p = 0.003). Five studies with 39.503 breast cancer patients and 372.037 controls were included in the ARBs user sub-group. Our results found significant different of antihypertensive drugs among breast cancer patient (OR = 1.47, 95% CI = 1.02–2.11 p = 0.04). Our data calculation also confirmed no significant different in antihypertensive drugs among breast cancer patient (OR = 1.07, 95% CI = 0.99–1.16, p = 0.09) in diuretics user, (OR = 1.08, 95% CI = 0.99–1.18, p = 0.08) in CCBs user, (OR = 1.11, 95% CI = 0.98–1.26, p = 0.09) in BBs user, and (OR = 1.27, 95% CI = 0.64–2.50, p = 0.50) in ACEIs user.

CONCLUSIONS: Although, the finding reveal that antihypertensive drugs (diuretics, CCBs, BBs, and ACEIs) in overall are significant for the risk of breast cancer and also found that ARBs have a low potential in the risk of breast cancer.
Publisher Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia
Date 2021-09-28
Type info:eu-repo/semantics/article
Format application/pdf
Source Open Access Macedonian Journal of Medical Sciences; Vol. 9 No. F (2021): F - Review Articles; 327-334
Language eng
Rights Copyright (c) 2021 Sinta Wiranata, Ida Ayu Widya Anjani, Putri Ayu Wulandari, Anak Agung Bagus Putra Indrakusuma, I Gede Krisna Arim Sadeva, Ayu Dilia Febriani Wisnawa, Jonny Karunia Fajar, I Putu Yuda Prabawa, Putu Anda Tusta Adiputra, I Wayan Sudarsa, Anak Agung Wiradewi Lestari, Desak Made Wihandani, I Gede Putu Supadmanaba (Author)

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us


Copyright © 2015-2018 Simon Fraser University Library